Welcome to our dedicated page for Inspira Technologies Oxy Bhn SEC filings (Ticker: IINN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. Inspira files Form 6-K current reports under the Securities Exchange Act of 1934, along with registration statements on Form F-3 and Form S-8 referenced in those reports. These filings document key events in the company’s development as a commercial-stage medical device and diagnostics business focused on respiratory support and blood monitoring.
Recent Form 6-K reports describe transactions such as a registered direct offering of ordinary shares and a Standby Equity Purchase Agreement that together outline Inspira’s equity financing tools. Other 6-Ks incorporate press releases on clinical and regulatory milestones, including progress with the HYLA non-invasive blood sensor, regulatory steps for the INSPIRA ART100 system in the United Arab Emirates, and financial results and business updates. Filings also cover shareholder meeting materials, board and executive changes, and adjustments to sales agreements for ordinary shares.
Through this page, users can review Inspira’s SEC-reported information on capital structure, financing arrangements, and material operational updates. Stock Titan’s tools can surface new 6-K submissions in real time and help summarize their contents, allowing readers to quickly understand how each filing relates to topics such as product commercialization, clinical studies, or corporate governance. For deeper analysis, investors can examine attachments referenced in the 6-Ks, including financial statements, management’s discussion and analysis, and opinions related to securities offerings.
IINN is amending its at-the-market offering program with A.G.P./Alliance Global Partners to increase the maximum aggregate offering price of its ordinary shares that may be sold under the existing sales agreement from $7,117,720 to $9,985,579.
The company has already sold ordinary shares for an aggregate of approximately $4,701,062 under the sales agreement. A.G.P. acts as sales agent on a best efforts basis, earning a 3.0% commission on the gross sales price per share, and is deemed an underwriter for these transactions. The amendment confirms that the company’s capacity to sell securities under its Form F-3 pursuant to General Instruction I.B.5 is $9,985,579, with the ordinary shares listed on the Nasdaq Capital Market under the symbol IINN.
Inspira Technologies Oxy B.H.N. Ltd. filed a report noting it has increased the maximum aggregate offering price of its ordinary shares that may be issued under its existing Sales Agreement with A.G.P./Alliance Global Partners from $7,117,720 to $9,985,579. This agreement allows the company to sell ordinary shares from time to time, and the change expands the total dollar amount of shares that can be issued through this program.
The company also filed a legal opinion from Sullivan & Worcester Tel-Aviv (Har-Even & Co.) confirming the legality of issuing and selling these ordinary shares under the Sales Agreement. This report is incorporated by reference into multiple existing registration statements on Form F-3 and Form S-8, meaning those registration statements now include this updated at-the-market capacity.